A subset of patients recruited in the main MATRIX study will be randomized after intervention
but before discharge to standard of care (the treating physician will decide which oral P2Y12
inhibitor will be added on top of aspirin) versus a customized approach based on an algorithm
which integrates phenotypic information, including but not limited to residual on-treatment
platelet reactivity assessed via VerifyNow P2Y12 Assay.